If-csatorna-gátlás - Új lehetoség az ischaemiás szívbetegség kezelésében

Translated title of the contribution: If-channel inhibition - A new approach in the treatment of ischaemic heart disease

Research output: Contribution to journalArticle

Abstract

Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.

Original languageHungarian
Pages (from-to)21-24
Number of pages4
JournalLege Artis Medicinae
Volume17
Issue numberSUPPL. 1
Publication statusPublished - 2007

Fingerprint

Myocardial Ischemia
Heart Rate
ivabradine
Sinoatrial Node
Hemodynamics
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

If-csatorna-gátlás - Új lehetoség az ischaemiás szívbetegség kezelésében. / Tóth, K.

In: Lege Artis Medicinae, Vol. 17, No. SUPPL. 1, 2007, p. 21-24.

Research output: Contribution to journalArticle

@article{59919c42269f47438baf8295fbb93ff5,
title = "If-csatorna-g{\'a}tl{\'a}s - {\'U}j lehetos{\'e}g az ischaemi{\'a}s sz{\'i}vbetegs{\'e}g kezel{\'e}s{\'e}ben",
abstract = "Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.",
keywords = "I inhibition, Ischaemic heart disease, Ivabradine",
author = "K. T{\'o}th",
year = "2007",
language = "Hungarian",
volume = "17",
pages = "21--24",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "SUPPL. 1",

}

TY - JOUR

T1 - If-csatorna-gátlás - Új lehetoség az ischaemiás szívbetegség kezelésében

AU - Tóth, K.

PY - 2007

Y1 - 2007

N2 - Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.

AB - Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.

KW - I inhibition

KW - Ischaemic heart disease

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=34249892214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249892214&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 21

EP - 24

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - SUPPL. 1

ER -